版本:
中国

BRIEF-Abbvie's investigational HCV regimen receives FDA Breakthrough Therapy Designation

Sept 30 Abbvie Inc :

* AbbVie's investigational HCV regimen receives U.S. FDA Breakthrough Therapy Designation Source text for Eikon: Further company coverage: ;))

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐